FMBA expects registration of the drug from COVID-19 "MIR 19" by the end of the year
Registration of the drug from the coronavirus "MIR 19" is expected by the end of the year, the press service of the Federal Medical and Biological Agency (FMBA) reported.
FMBA is awaiting registration of the drug from COVID-19 "MIR
"Registration is planned before the end of this year," - quoted by RIA Novosti press service.
Earlier it was reported that the Institute of Immunology FMBA submitted documents for registration of the drug from COVID-19 "MIR 19".
The first phase of human clinical trials was completed in March this year and showed the safety of MIR 19.